中国卫生标准管理
中國衛生標準管理
중국위생표준관리
CHINA HEALTH STANDARD MANAGEMENT
2014年
15期
91-93
,共3页
脑梗死%奥拉西坦%依达拉奉%认知功能障碍
腦梗死%奧拉西坦%依達拉奉%認知功能障礙
뇌경사%오랍서탄%의체랍봉%인지공능장애
Infarction%Oxiracetam%Edaravone%Cognitive dysfunction
目的：评价奥拉西坦联合依达拉奉治疗脑梗死伴轻度认知功能障碍患者的临床疗效。方法将入选的96例患者随机分为两组，治疗组48例，在常规治疗基础上应用奥拉西坦4 g加生理盐水200 ml静滴，1次/d；依达拉奉30 mg加生理盐水100 ml静滴，2次/d；均治疗3周，4周后进行疗效评定。结果治疗3周后，两组MMSE、BI分值均较治疗前明显提高（P<0.05）；治疗组提高更明显（P<0.01）；且治疗组明显高于对照组（P<0.05）；结论奥拉西坦联合依达拉奉可显著改善脑梗死患者的认知功能障碍。
目的：評價奧拉西坦聯閤依達拉奉治療腦梗死伴輕度認知功能障礙患者的臨床療效。方法將入選的96例患者隨機分為兩組，治療組48例，在常規治療基礎上應用奧拉西坦4 g加生理鹽水200 ml靜滴，1次/d；依達拉奉30 mg加生理鹽水100 ml靜滴，2次/d；均治療3週，4週後進行療效評定。結果治療3週後，兩組MMSE、BI分值均較治療前明顯提高（P<0.05）；治療組提高更明顯（P<0.01）；且治療組明顯高于對照組（P<0.05）；結論奧拉西坦聯閤依達拉奉可顯著改善腦梗死患者的認知功能障礙。
목적：평개오랍서탄연합의체랍봉치료뇌경사반경도인지공능장애환자적림상료효。방법장입선적96례환자수궤분위량조，치료조48례，재상규치료기출상응용오랍서탄4 g가생리염수200 ml정적，1차/d；의체랍봉30 mg가생리염수100 ml정적，2차/d；균치료3주，4주후진행료효평정。결과치료3주후，량조MMSE、BI분치균교치료전명현제고（P<0.05）；치료조제고경명현（P<0.01）；차치료조명현고우대조조（P<0.05）；결론오랍서탄연합의체랍봉가현저개선뇌경사환자적인지공능장애。
Objective evaluate the clinical efficacy of cerebral infarction in patients with mild cognitive impairment of Oxiracetamedaravone treatment.Method wil be selected 96 patients were randomly divided into two groups, the treatment group, 48 patients in the conventional treatment applications based on Oxiracetam 4g intravenous normal saline 200ml, 1 times/d; edaravone 30mg intravenous normal saline 100ml, 2 times/d; were treated for three weeks, efficacy was assessed after 4 weeks.Results After three weeks, both groups MMSE, BI scores than before treatment significantly increased (P<0.05); treatment group improved more significantly (P<0.01); and the treatment group was significantly higher (P< 0.05).Conclusion oxiracetamedaravone significantly improve cognitive dysfunction in patients with cerebral infarction.
